Terms of service

This portal provides product information and access exclusively to licensed healthcare professionals. The following is a summary of the key terms that govern your use of this site. It is not a substitute for the full Policy Pack, which you are encouraged to read in its entirety.


Who may access this portal
  • You must hold a current, valid professional licence or registration in your jurisdiction, in good standing with your regulatory body.
  • Account applications are subject to independent verification of your licence status, registration number, and institutional details.
  • Access is not available to members of the general public. Any order that appears to originate from a non-practitioner will be cancelled and refunded.
  • Approval grants the right to purchase for professional use, recommendation, or dispensing within your own practice only — not for resale or redistribution to third parties.

About the product

Enhanced Nanocelle NanoCBD is an ingestible hemp-derived cannabidiol (CBD) product formulated using nanocelle/nanoemulsion technology, containing no more than 0.3% delta-9 THC by dry weight, consistent with the US 2018 Farm Bill. A batch-specific Certificate of Analysis (COA) from an accredited independent laboratory is available for every shipment on request.

No medical claims are made or should be implied. All clinical decisions regarding recommendation, dispensing, or prescription remain the sole professional responsibility of the treating practitioner.


Jurisdiction-specific conditions

United States
Hemp-derived CBD supplied B2B under the 2018 Farm Bill. State-law compliance is the practitioner's responsibility. Patients must be 21 years of age or older.
United Kingdom
Structured as a professional-responsibility import. No FSA Novel Food authorisation is currently held. UK practitioners import under their own professional judgment and regulatory responsibility.
Australia
Supply only via Authorised Prescriber approval or TGA Special Access Scheme Category B (SAS-B) notification, on a named-patient basis. No general practice stocking.
Canada
Interim professional-responsibility basis. CBD is classified as cannabis under the Cannabis Act. Practitioners accept responsibility for confirming import compliance prior to ordering.

Orders, returns and privacy
  • Prices exclude duties, customs charges, and local taxes. Risk passes to the practitioner on dispatch. For international shipments, the practitioner is the importer of record.
  • Damaged or incorrect orders must be reported within 14 days of delivery. Unopened product in original packaging may be returned within 30 days (return authorisation required). Opened or used product is non-returnable.
  • We collect practitioner identity, licence, and order information for verification, fulfilment, and regulatory compliance. We do not collect or store patient health information.
  • Practitioners in the UK, Canada, and Australia hold data rights under UK GDPR, PIPEDA, and the Australian Privacy Act respectively. Data is processed in the United States.
  • These terms are governed by the laws of the State of Florida, USA. Material changes will be notified by email at least 14 days before taking effect.

The above is provided as an overview for ease of reference. The complete Practitioner Channel Terms, Conditions & Compliance Policy Pack — covering your full attestation obligations, jurisdiction-specific legal bases, liability provisions, and privacy rights — constitutes the binding agreement governing your access to and use of this portal. We encourage all registered practitioners to read it carefully. View the full terms and conditions here. By continuing to use this portal or placing an order, you confirm that you have read, understood, and agreed to those terms in full.